Teva Struggles To Sell 2014 Guidance, Blue-Sky Estimates For NTE Program
Executive Summary
The Israeli generics giant unveiled two sets of 2014 guidance, allowing for different levels of competition for Copaxone. But Wall Street sees the company slowing the pace of cost-cutting and providing overly optimistic revenue estimates for new therapeutic entities.
You may also be interested in...
A More Disciplined Teva Gets Lukewarm Reception From Street
More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.